IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of "Moderate Buy" by Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the thirteen brokerages that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $48.0909.

A number of research firms have recently weighed in on IDYA. Wells Fargo & Company initiated coverage on IDEAYA Biosciences in a research note on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target for the company. JPMorgan Chase & Co. increased their price objective on IDEAYA Biosciences from $66.00 to $72.00 and gave the company an "overweight" rating in a report on Monday, July 28th. The Goldman Sachs Group raised IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective on the stock in a report on Thursday, July 10th. TD Cowen initiated coverage on IDEAYA Biosciences in a report on Tuesday, July 22nd. They set a "buy" rating on the stock. Finally, Royal Bank Of Canada raised IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and lowered their price objective for the company from $57.00 to $30.00 in a report on Wednesday, July 9th.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in IDEAYA Biosciences by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 7,483 shares of the company's stock worth $123,000 after acquiring an additional 627 shares during the last quarter. CWM LLC grew its holdings in IDEAYA Biosciences by 33.0% during the 2nd quarter. CWM LLC now owns 3,153 shares of the company's stock worth $66,000 after acquiring an additional 782 shares during the last quarter. Mariner LLC grew its holdings in IDEAYA Biosciences by 9.8% during the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after acquiring an additional 869 shares during the last quarter. Swiss National Bank grew its holdings in IDEAYA Biosciences by 0.8% during the 1st quarter. Swiss National Bank now owns 150,800 shares of the company's stock worth $2,470,000 after acquiring an additional 1,200 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in IDEAYA Biosciences by 6.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,301 shares of the company's stock worth $349,000 after acquiring an additional 1,214 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Trading Up 3.0%

Shares of IDEAYA Biosciences stock opened at $25.00 on Tuesday. The stock has a 50-day moving average price of $22.19 and a 200 day moving average price of $20.33. The company has a market cap of $2.19 billion, a P/E ratio of -6.96 and a beta of 0.09. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $40.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the prior year, the firm earned ($0.53) earnings per share. On average, equities analysts forecast that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.